GNI Group Ltd. provided an update on the subject enrollment in Phase III clinical trial in China of F351 (generic name: Hydronidone) for HBV-induced liver fibrosis conducted by one of main subsidiaries, Beijing Continent Pharmaceuticals Co. Ltd. As of May 19, 2023, Continent has completed the enrollments of 124 subjects, which is 50% of the target enrollment.